Prosecution Insights
Last updated: November 04, 2026
Application No. 18/017,006

BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES

Final Rejection §102
Filed
Jan 19, 2023
Priority
Jul 20, 2020 — provisional 63/054,218 +1 more
Examiner
SEITZ, ANTHONY JOSEPH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Albany College Of Pharmacy And Health Sciences In The City Of Albany
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
148 granted / 217 resolved
+8.2% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
279
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
27.6%
-12.4% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 217 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election of Species and Status of the Claims Claims 1-2, 6, 10-11, 13, 15-18, 23-27, 29, 33, 39, 42, and 46 are pending. Claims 13, 15-16, 39, 42, and 46 are withdrawn from further consideration as being directed towards nonelected species until a generic claim has been found allowable. Claims 1-2, 6, 10-11, 17-18, 23-27, 29, and 33 are examined on their merits. 35 U.S.C. § 112(b) Rejections Overcome by Amendment Applicant’s amendment to claim 17 in the response filed on June 29th 2026 is acknowledged. Applicant has amended the claim to no longer recite a blank, thus overcoming the 112(b) rejection over the claim. The 112(b) rejection over claim 17 is thereby withdrawn. 35 U.S.C. § 102 Rejections Overcome by Amendment Applicant’s amendments in the response filed on June 29th 2026 are acknowledged. Applicant has amended the claims to no longer include the aryl substituent in the R2 location, as required by Nomura. Nomura is no longer anticipatory of the claims and all 102 rejections are thereby withdrawn. 35 U.S.C. § 103 Rejections Overcome by Amendment Applicant’s amendments in the response filed on June 29th 2026 are acknowledged. Applicant has amended the claims to no longer recite the spiro-condensed core, as was the basis of the 103 rejections. Applicant has thus overcome the 103 rejections over Petrukhin, and all 103 rejections are thereby withdrawn. Nonstatutory Double Patenting Rejections Overcome by Amendment As the nonstatutory double patenting rejections were made on the same basis as the 103 rejections, they are each withdrawn for the same reasons. 35 U.S.C. § 102 Rejections Necessitated by Amendment In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, and 6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Harada (WO2002098872A1 published on December 12th 2002; Google Patents Translation Attached). Harada teaches the compound, PNG media_image1.png 397 500 media_image1.png Greyscale (Harada, pg. 40, 2_ (4-benzyloxypiperidine-11-yl) benzoic acid · sodium salt). Harada’s compound is anticipatory of claims 1, 2, and 6. Claims 1, 2, 6, and 23 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Boehm (WO2011088201A1 published on July 21st 2011). Boehm teaches the compound, PNG media_image2.png 324 500 media_image2.png Greyscale (Boehm, Claim 29, 1-Methylethyl 2-((3S)-3-{[(2-ethylphenyl)methyl]amino}-1-pyrrolidinyl)-3- pyridinecarboxylate). Boehm’s compound is anticipatory of claims 1, 2, and 6. Boehm additionally teaches a pharmaceutical composition comprising the compound (Boehm, claim 30), anticipating claim 23. Allowable Subject Matter Claims 10-11, 17-18, 24-27, 29, and 33 are free of the prior art. Applicant has developed compounds of the generic formula, PNG media_image3.png 277 122 media_image3.png Greyscale . Such compounds act as antagonists of retinol-binding protein 4, thus stabilizing the transthyretin (TTR) complex and allowing for the treatment of various ocular diseases, such as macular degeneration. Certain aspects of applicant’s generic formula have been found in the art (see the above 102 rejections). However, applicant provides the first instance of RBP4 antagonists belonging to the above compound genus. Additionally, applicant’s particular compounds as described in claims 10, 11, and 17 are not found in the art, nor are they predictable from the art. Claims 10-11, 17-18, 24-27, 29, and 33 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anthony Seitz whose telephone number is (703)756-4657. The examiner can normally be reached 7:30 AM ET - 5:00 PM ET M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.J.S./Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Jan 19, 2023
Application Filed
Mar 01, 2024
Response after Non-Final Action
Mar 08, 2024
Response after Non-Final Action
Mar 27, 2026
Non-Final Rejection mailed — §102
Jun 29, 2026
Response Filed
Oct 05, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758536
COMBINATION OF A SK2 INHIBITOR AND AN INHIBITOR OF A CHECKPOINT PATHWAY, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
5y 3m to grant Granted Oct 13, 2026
Patent 12759985
COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES
2y 10m to grant Granted Oct 13, 2026
Patent 12760035
COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF
3y 1m to grant Granted Oct 13, 2026
Patent 12760020
SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF
2y 8m to grant Granted Oct 13, 2026
Patent 12751938
THERAPEUTIC USES OF INHIBITORS OF THE RNA-BINDING PROTEIN HuR
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
95%
With Interview (+26.9%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 217 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month